Cargando…
Safety, Immunogenicity and Duration of Protection of the RTS,S/AS02(D) Malaria Vaccine: One Year Follow-Up of a Randomized Controlled Phase I/IIb Trial
BACKGROUND: The RTS,S/AS02(D) vaccine has been shown to have a promising safety profile, to be immunogenic and to confer protection against malaria in children and infants. METHODS AND FINDINGS: We did a randomized, controlled, phase I/IIb trial of RTS,S/AS02(D) given at 10, 14 and 18 weeks of age s...
Autores principales: | Aide, Pedro, Aponte, John J., Renom, Montse, Nhampossa, Tacilta, Sacarlal, Jahit, Mandomando, Inacio, Bassat, Quique, Manaca, Maria Nélia, Leach, Amanda, Lievens, Marc, Vekemans, Johan, Dubois, Marie-Claude, Loucq, Christian, Ballou, W. Ripley, Cohen, Joe, Alonso, Pedro L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2973956/ https://www.ncbi.nlm.nih.gov/pubmed/21079803 http://dx.doi.org/10.1371/journal.pone.0013838 |
Ejemplares similares
-
Insights into Long-Lasting Protection Induced by RTS,S/AS02A Malaria Vaccine: Further Results from a Phase IIb Trial in Mozambican Children
por: Guinovart, Caterina, et al.
Publicado: (2009) -
Malaria in rural Mozambique. Part I: Children attending the outpatient clinic
por: Guinovart, Caterina, et al.
Publicado: (2008) -
Malaria in rural Mozambique. Part II: children admitted to hospital
por: Bassat, Quique, et al.
Publicado: (2008) -
Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial
por: Macete, Eusebio V, et al.
Publicado: (2007) -
RTS,S/AS02A Malaria Vaccine Does Not Induce Parasite CSP T Cell Epitope Selection and Reduces Multiplicity of Infection
por: Enosse, Sonia, et al.
Publicado: (2006)